Protective effect of IL-18 on kainate- and IL-1β-induced cerebellar ataxia in mice

Journal of Immunology

Volumn 180, Issue 4, 2008, Pages 2322-2328

  Andoh, Tsugunobu ^a   Kishi, Hiroyuki ^b   Motoki, Kazumi ^b   Nakanishi, Kenji ^c   Kuraishi, Yasushi ^a   Muraguchi, Atsushi ^b  

^a Department of Applied Pharmacology ^*  (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; KAINIC ACID; MYELOID DIFFERENTIATION FACTOR 88;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLAR ATAXIA; CEREBELLUM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; MALE; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; CASPASE 1; CEREBELLAR ATAXIA; CEREBELLUM; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; INTERLEUKIN-18; INTERLEUKIN-1BETA; KAINIC ACID; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 42149157789     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.4.2322     Document Type: Article

References (49)

1. Ben-Ari, Y., and R. Cossart. 2000. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci. 23: 580-587.
2. Mulle, C., A. Sailer, I. Pérez-Otaño, H. Dickinson-Anson, P. E. Castillo, I. Bureau, C. Maron, F. H. Gage, J. R. Mann, B. Bettler, and S. F. Hainemann. 1998. Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice. Nature 392: 601-605.
3. Bettler, B., and C. Mulle. 1995. Review: neurotransmitter receptors: II. AMPA and kainate receptors. Neuropharmacology 34: 123-139.
4. Lerma, J., M. Morales, M. A. Vicente, and O. Herreras. 1997. Glutamate receptors of the kainate type and synaptic transmission. Trends Neurosci. 20: 9-12.
5. Bahn, S., B. Volk, and W. Wisden. 1994. Kainate receptor gene expression in the developing rat brain. J. Neurosci. 14: 5525-5547.
6. Bettler, B., J. Boulter, I. Hermans-Borgmeyer, A. O'Shea-Greenfield, E. S. Deneris, C. Moll, U. Borgmeyer, M. Hollmann, and S. Heinemann. 1990. Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development. Neuron 5: 583-595.
7. Egebjerg, J., B. Bettler, I. Hermans-Borgmeyer, and S. Heinemann. 1991. Cloning of a cDNA for a glutamate receptor subunit activated by kainate but not AMPA. Nature 351: 745-748.
8. Feldmeyer, D., and S. Cull-Candy. Neurotransmitters: elusive glutamate receptors. 1994. Curr. Biol. 4: 82-84.
9. Herb, A., N. Burnashev, P. Werner, B. Sakmann, W. Sisden, and P. H. Seeburg. 1992. The KA-2 subunit of excitatory amino acid receptors shows widespread expression in brain and forms ion channels with distantly related subunits. Neuron 8: 775-785.
10. Werner, P., M. Voigt, K. Keinanen, W. Wisden, and P. H. Seeburg. 1991. Cloning of a putative high-affinity kainate receptor expressed predominantly in hippocampal CA3 cells. Nature 351: 742-744.
11. Meldrum, B., and J. Garthwaite. 1990. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11: 379-387.
12. Dinarello, C. A. 1998. Interleukin-1 β, interleukin-18, and the interleukin-1 β converting enzyme. Ann. NY Acad. Sci. 856: 1-11.
13. Jander, S., M. Schroeter, and G. Stoll. 2002. Interleukin-18 expression after focal ischemia of the rat brain: association with the late-stage inflammatory response. J. Cereb. Blood Flow Metab. 22: 62-70.
14. Neveu, P. J., and S. Liége. 2000. Mechanisms of behavioral and neuroendocrine effects of interleukin-1 in mice. Ann. NY Acad. Sci. 917: 175-185.
15. Patel, H. C., H. Boutin, and S. M. Allan. 2003. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann. NY Acad. Sci. 992: 39-47.
16. Minami, M., Y. Kuraishi, T. Yamaguchi, S. Nakai, Y. Hirai, and M. Satoh. 1990. Convulsants induce interleukin-1 β messenger RNA in rat brain. Biochem. Biophys. Res. Commun. 171: 832-837.
17. Nishiyori, A., M. Minami, S. Takami, and M. Satoh. 1997. Type 2 interleukin-1 receptor mRNA is induced by kainic acid in the rat brain. Brain Res. Mol. Brain Res. 50: 237-245.
18. Eriksson, C., R. Tehranian, K. Iverfeldt, B. Winblad, and M. Schultzberg. 2000. Increased expression of mRNA encoding interleukin-1β and caspase-1, and the secreted isoform of interleukin-1 receptor antagonist in the rat brain following systemic kainic acid administration. J. Neurosci. Res. 60: 266-279.
19. Vezzani, A., M. Conti, A. De Luigi, T. Ravizza, D. Moneta, F. Marchesi, and M. G. De Simoni. 1999. Interleukin-1β immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J. Neurosci. 19: 5054-5065.
20. Vezzani, A., D. Moneta, M. Conti, C. Richichi, T. Ravizza, A. De Luigi, M. G. De Simoni, G. Sperk, S. Andell-Jonsson, J. Lundkvist, et al. 2000. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc. Natl. Acad. Sci. USA 97: 11534-11539.
21. Felderhoff-Mueser, U., O. I. Schmidt, A. Oberholzer, C. Buhrer, and P. F. Stahel. 2005. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. 28: 487-493.
22. Duenas, A. M., R. Goold, and P. Giunti. 2006. Molecular pathogenesis of spinocerebellar ataxias. Brain 129: 1357-1370.
23. Taylor, A. M., and P. J. Byrd. 2005. Molecular pathology of ataxia telangiectasia. J. Clin. Pathol. 58: 1009-1015.
24. Kuida, K., J. A. Lippke, G. Ku, M. W. Harding, D. J. Livingston, M. S. Su, and R. A. Flavell. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1 β converting enzyme. Science 267: 2000-2003.
25. Hoshino, K., H. Tsutsui, T. Kawai, K. Takeda, K. Nakanishi, Y. Takeda, and S. Akira. 1999. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 162: 5041-5044.
26. Pietraszek, M., A. Gravius, D. Schafer, T. Weil, D. Trifanova, and W. Danysz. 2005. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49: 73-85.
27. Minami, M., Y. Kuraishi, and M. Satoh. 1991. Effects of kainic acid on messenger RNA levels of IL-1 β, IL-6, TNF α, and LIF in the rat brain. Biochem. Biophys. Res. Commun. 176: 593-598.
28. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
29. Gu, Y., K. Kuida, H. Tsutsui, G. Ku, K. Hsiao, M. A. Fleming, N. Hayashi, K. Higashino, H. Okamura, K. Nakanishi, et al. 1997. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 275: 206-209.
30. Hamilton, B. A., W. N. Frankel, A. W. Kerrebrock, T. L. Hawkins, W. FitzHugh, K. Kusumi, L. B. Russell, K. L. Mueller, V. van Berkel, B. W. Birren, et al. 1996. Disruption of the nuclear hormone receptor RORα in staggerer mice. Nature 379: 736-739.
31. Zuo, J., P. L. De Jager, K. A. Takahashi, W. Jiang, D. J. Linden, and N. Heintz. 1997. Neurodegeneration in Lurcher mice caused by mutation in δ2 glutamate receptor gene. Nature 388: 769-773.
32. Vernet-der Garabedian, B., Y. Lemaigre-Dubreuil, N. Delhaye-Bouchaud, and J. Mariani. 1998. Abnormal IL-1β cytokine expression in the cerebellum of the ataxic mutant mice staggerer and lurcher. Brain Res. Mol. Brain Res. 62: 224-227.
33. Miller, L. G., and J. M. Fahey. 1994. Interleukin-1 modulates GABAergic and glutamatergic function in brain. Ann. NY Acad. Sci. 739: 292-298.
34. Gabbott, P. L., J. Somogyi, M. G. Stewart, and J. Hamori. 1986. GABA-immunoreactive neurons in the rat cerebellum: a light and electron microscope study. J. Comp. Neurol. 251: 474-490.
35. Cheron, G., L. Servais, J. Wagstaff, and B. Dan. 2005. Fast cerebellar oscillation associated with ataxia in a mouse model of Angelman syndrome. Neuroscience 130: 631-637.
36. Sims, J. E., M. J. Nicklin, J. F. Bazan, J. L. Barton, S. J. Busfield, J. E. Ford, R. A. Kastelein, S. Kumar, H. Lin, J. J. Mulero, et al. 2001. A new nomenclature for IL-1-family genes. Trends Immunol. 22: 536-537.
37. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
38. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17: 1-14.
39. Yamamoto, M., S. Sato, H. Hemmi, S. Uematsu, K. Hoshino, T. Kaisho, O. Takeuchi, K. Takeda, and S. Akira. 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 4: 1144-1150.
40. Mehta, V. B., J. Hart, and M. D. Wewers. 2001. ATP-stimulated release of interleukin (IL)-1β and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J. Biol. Chem. 276: 3820-3826.
41. Murgia, M., S. Hanau, P. Pizzo, M. Rippa, and F. Di Virgilio. 1993. Oxidized ATP: an irreversible inhibitor of the macrophage purinergic P2Z receptor. J. Biol. Chem. 268: 8199-8203.
42. Nicklas, W. J., B. Krespan, and S. Berl. 1980. Effect of kainate on ATP levels and glutamate metabolism in cerebellar slices. Eur. J. Pharmacol. 62: 209-213.
43. Bowie, A., and L. A. O'Neill. 2000. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J. Leukocyte Biol. 67: 508-514.
44. Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5: 373-379.
45. Thomassen, E., B. R. Renshaw, and J. E. Sims. 1999. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11: 389-399.
46. Brint, E. K., K. A. Fitzgerald, P. Smith, A. J. Coyle, J. C. Gutierrez-Ramos, P. G. Fallon, and L. A. O'Neill. 2002. Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2: a role for Jun N-terminal kinase in IL-4 induction. J. Biol. Chem. 277: 49205-49211.
47. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313-320.
48. Zhang, X. M., R. S. Duan, Z. Chen, H. C. Quezada, E. Mix, B. Winblad, and J. Zhu. 2007. IL-18 deficiency aggravates kainic acid-induced hippocampal neurodegeneration in C57BL/6 mice due to an overcompensation by IL-12. Exp. Neurol. 205: 64-73.
49. Yang, D. D., C. Y. Kuan, A. J. Whitmarsh, M. Rincon, T. S. Zheng, R. J. Davis, P. Rakic, and R. A. Flavell. 1997. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389: 865-870.